ATE439797T1 - Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstírungen durch veränderung der atypischen pkm-aktivität - Google Patents

Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstírungen durch veränderung der atypischen pkm-aktivität

Info

Publication number
ATE439797T1
ATE439797T1 AT02734079T AT02734079T ATE439797T1 AT E439797 T1 ATE439797 T1 AT E439797T1 AT 02734079 T AT02734079 T AT 02734079T AT 02734079 T AT02734079 T AT 02734079T AT E439797 T1 ATE439797 T1 AT E439797T1
Authority
AT
Austria
Prior art keywords
memory
psychiatric
altering
relief
functional disorders
Prior art date
Application number
AT02734079T
Other languages
English (en)
Inventor
Jerry Yin
Eric Drier
Todd Sacktor
Original Assignee
Cold Spring Harbor Lab
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab, Univ New York State Res Found filed Critical Cold Spring Harbor Lab
Application granted granted Critical
Publication of ATE439797T1 publication Critical patent/ATE439797T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Semiconductor Memories (AREA)
AT02734079T 2001-04-27 2002-04-29 Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstírungen durch veränderung der atypischen pkm-aktivität ATE439797T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28716501P 2001-04-27 2001-04-27
US32694801P 2001-10-04 2001-10-04
PCT/US2002/013451 WO2002087417A2 (en) 2001-04-27 2002-04-29 Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity

Publications (1)

Publication Number Publication Date
ATE439797T1 true ATE439797T1 (de) 2009-09-15

Family

ID=26964304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02734079T ATE439797T1 (de) 2001-04-27 2002-04-29 Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstírungen durch veränderung der atypischen pkm-aktivität

Country Status (8)

Country Link
US (1) US7378090B2 (de)
EP (2) EP1389941B1 (de)
AT (1) ATE439797T1 (de)
AU (1) AU2002305269B2 (de)
CA (1) CA2449794A1 (de)
DE (1) DE60233398D1 (de)
ES (1) ES2329117T3 (de)
WO (1) WO2002087417A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455185T1 (de) * 2002-11-01 2010-01-15 Univ New York State Res Found Atypische protein-kinase-c-isoformen bei erkrankungen des nervensystems und krebs
WO2008019395A2 (en) * 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
EP2354789A1 (de) 2010-02-08 2011-08-10 Sygnis Bioscience GmbH & Co. KG Verfahren zur Identifizierung von gedächtnismodulierenden Verbindungen durch Auswertung der KIBRA-Expression
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959096A (en) * 1992-03-16 1999-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
JPH06508154A (ja) * 1992-04-06 1994-09-14 グラクソ、ソシエダッド、アノニマ ペプチド
US5786362A (en) * 1994-06-16 1998-07-28 University Of Miami Method of treating Hormone independent cancer
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
EP1276494A4 (de) * 2000-04-20 2005-02-09 Todd C Sacktor GEDäCHTNIS-VERBESSERNDES PROTEIN
US7928070B2 (en) * 2000-04-20 2011-04-19 The Research Foundation Of State University Of Ny Memory enhancing protein

Also Published As

Publication number Publication date
US20030068310A1 (en) 2003-04-10
EP1389941A4 (de) 2006-11-15
DE60233398D1 (de) 2009-10-01
AU2002305269B2 (en) 2006-10-19
EP1389941B1 (de) 2009-08-19
US7378090B2 (en) 2008-05-27
EP1389941A2 (de) 2004-02-25
ES2329117T3 (es) 2009-11-23
WO2002087417A2 (en) 2002-11-07
WO2002087417A3 (en) 2003-12-18
AU2002305269C1 (en) 2002-11-11
EP2103626A1 (de) 2009-09-23
CA2449794A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
AT500802A3 (de) Gesicherte biometrische überprüfung von identität-kreuzverweisen zur verwandten anwendungen
DK1446387T3 (da) Substituerede aryl, 1,4-pyrazinderivater
ATE412642T1 (de) Inhibitoren von p-38-kinase
ATE512428T1 (de) Regelung des zugriffs auf einen bereich
ATE367097T1 (de) Verwendung von füllstoffe als sättigungsmittel
DE69839534D1 (de) Sulfonamide zur Behandlung von durch Endothelin vermittelten Störungen
ATE297917T1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60219961D1 (de) Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
ATE360013T1 (de) Aryliden und heteroaryliden-oxindolderivate als tyrosin kinase inhibitoren
ATE362473T1 (de) 1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten
ATE297731T1 (de) Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol
DE60234116D1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
NO20023573L (no) Sann relativ amplitudemigrering
BRPI0607304A2 (pt) compostos tendo atividade analgésica e/ou imunoestimulante
DE60300021D1 (de) (S)-4-Amino-5-Chloro-2-Methoxy-N-[1-[1-(2-Tetrahydrofuryl-Carbonyl)-4-Piperidinylmethyl]-4-Piperidinyl]benzamid zur Behandlung von Magen-Darmbewegungskrankheiten
ATE439797T1 (de) Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstírungen durch veränderung der atypischen pkm-aktivität
AR037402A1 (es) Derivados de 4-(oxadiazol-3-il)-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion en terapeutica
DE69918413D1 (de) Auswahlverfahren von hla-g exprimierenden tumoren, die durch antikrebsmittel behandelbar sind, und deren verwendungen
DE60330262D1 (de) Vorrichtung zur erleichterung und authentifizierung von transaktionen
CY1107039T1 (el) Αναστολεις τριπεπτιδυλ πεπτιδασης
DK1471916T3 (da) Behandling af rheumatoid arthritis under anvendelse af imatinib
FR2818747B1 (fr) Procede de criblage base sur l'interaction siah-numb
NO20040935L (no) Plaster for behandling av dysfunksjoner og forstyrrelser i negler.
DK1278728T3 (da) Pyrrolidin- og piperidinderivater samt anvendelse deraf til behandling af neurodegenerative lidelser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1389941

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1389941

Country of ref document: EP

REN Ceased due to non-payment of the annual fee